In what is believed to be the most comprehensive molecular characterization to date of HPV-negative head and neck squamous cell carcinomas (HNSCCs), researchers have clarified the contribution of key cancer-associated genes, proteins and signaling pathways in these cancers, while proposing possible new treatment avenues.
According to new research from investigators with the Johns Hopkins Kimmel Cancer Center and its Bloomberg-Kimmel Institute for Cancer Immunotherapy, a microbe found in the colon and commonly associated with the development of colitis and colon cancer also may play a role in the development of some breast cancers.
The International Duration of Adjuvant Chemotherapy (IDEA) collaboration investigated whether 3-month adjuvant chemotherapy treatment can be given for colon cancer without compromising efficacy, as six-month adjuvant chemotherapy with a fluoropyrimidine and oxaliplatin doublet is an option for high-risk stage II colon cancer. Here are the results.
The Healthy Eating Index (HEI) is a diagnostic indicator (0-100) of how well Americans conform to dietary advice, and the latest US numbers in 2015 were low: 59. Older Americans were better than young, but the fact remains we could all do better with the choices we’re making in our daily intake. Here are five […]
A neurologist shares his experience receiving the first dose of the vaccine and what he felt during those 15 minutes of observation time. He had some reservations about the safety of the new vaccine, so was he about to become a statistic in the next FDA safety bulletin? Read on to discover the side effect […]
These evidence-based guidelines from the American Society of Hematology (ASH), the International Society on Thrombosis and Haemostasis (ISTH), the National Hemophilia Foundation (NHF), and the World Federation of Hemophilia (WFH) are intended to support patients, clinicians, and health care professionals in their decisions about management of VWD, a common inherited bleeding disorder.
The term abscopal effect (from Latin, ab, meaning “away from,” and scopus, meaning “target”) was coined in 1953, specifically referring to effects of ionizing radiation outside the radiated tumor volume. Does the evidence show that, contrary to widely held perception in the field, the abscopal effect is exceedingly rare and is not clinically relevant when […]
From the pages of Clinical Advances in Hematology & Oncology comes this Q&A with Jennifer A. Woyach, MD, a Professor of Medicine in the Division of Hematology at the Ohio State University Comprehensive Cancer Center. Dr. Woyach provides extensive commentary on BTK, BCL2, and PI3K inhibitors, FCR usage, and the importance of clinical trials when […]
In June 2020, the US Food and Drug Administration (FDA) granted accelerated approval to tazemetostat (Tazverik, Epizyme), an oral EZH2 inhibitor for the treatment of adult patients with relapsed/refractory follicular lymphoma. Clinical Advances in Hematology & Oncology takes a closer look at this new treatment through a conversation with Dr. Connie Lee Batlevi from MSKCC.
At the 18th Annual 2020 Medical Innovation Summit, experts led by Will Morris, MD, executive medical director for Cleveland Clinic Innovations, and Akhil Saklecha, MD, managing director of Cleveland Clinic Ventures, recognized the top 10 medical advances for 2021. Drum roll, please! Do you agree with the choices?